(Q38703578)

5 September 2017

title

The selective estrogen receptor modulators in breast cancer prevention (English)

1 reference

5 September 2017

Fangxuan Li

1

1 reference

5 September 2017

Jinli Dou

2

1 reference

5 September 2017

Lijuan Wei

3

1 reference

5 September 2017

Shixia Li

4

1 reference

5 September 2017

Juntian Liu

5

1 reference

5 September 2017

publication date

20 January 2016

1 reference

Cancer Chemotherapy and Pharmacology

5 September 2017

published in

1 reference

5 September 2017

volume

77

1 reference

5 September 2017

issue

5

1 reference

5 September 2017

page(s)

895-903

1 reference

https://scigraph.springernature.com/pub.10.1007/s00280-016-2959-0

5 September 2017

exact match

0 references

cites work

Costs, evidence, and value in the Medicare program: the challenges of technology innovation in breast cancer prevention and control

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-2959-0

Breast cancer statistics, 2013.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-2959-0

Estrogen carcinogenesis in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-2959-0

Combined associations of genetic and environmental risk factors: implications for prevention of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-2959-0

Tamoxifen vs Raloxifene vs Exemestane for Chemoprevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-2959-0

Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-2959-0

Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-2959-0

Italian randomized trial among women with hysterectomy: tamoxifen and hormone-dependent breast cancer in high-risk women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-2959-0

Tamoxifen for the prevention of breast cancer: late results of the Italian Randomized Tamoxifen Prevention Trial among women with hysterectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-2959-0

Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-2959-0

Long-term results of tamoxifen prophylaxis for breast cancer--96-month follow-up of the randomized IBIS-I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-2959-0

First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-2959-0

Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-2959-0

BRCA1 Mutations and Breast Cancer in the General Population

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-2959-0

Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-2959-0

Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-2959-0

National comprehensive cancer network

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-2959-0

Breast cancer prevention for BRCA1 and BRCA2 mutation carriers: is there a role for tamoxifen?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-2959-0

Overview of the main outcomes in breast-cancer prevention trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-2959-0

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-2959-0

A randomized trial of low-dose tamoxifen on breast cancer proliferation and blood estrogenic biomarkers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-2959-0

Effects of low dose tamoxifen on normal breast tissue from premenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-2959-0

Randomized dose-ranging trial of tamoxifen at low doses in hormone replacement therapy users.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-2959-0

A phase-III prevention trial of low-dose tamoxifen in postmenopausal hormone replacement therapy users: the HOT study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-2959-0

Tamoxifen should be cost-effective in reducing breast cancer risk in high-risk women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-2959-0

Atypical hyperplasia of the breast--risk assessment and management options

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-2959-0

Tamoxifen for breast cancer prevention: a framework for clinical decisions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-2959-0

Chemoprevention: drug pricing and mortality: the case of tamoxifen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-2959-0

The benefits and costs of tamoxifen for breast cancer prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-2959-0

Economic evaluation of chemoprevention of breast cancer with tamoxifen and raloxifene among high-risk women in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-2959-0

The STAR trial: evidence for raloxifene as a breast cancer risk reduction agent for postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-2959-0

Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-2959-0

Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-2959-0

Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-2959-0

Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-2959-0

Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-2959-0

Lasofoxifene in postmenopausal women with osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-2959-0

Breast cancer incidence in the randomized PEARL trial of lasofoxifene in postmenopausal osteoporotic women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-2959-0

Arzoxifene for prevention of fractures and invasive breast cancer in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-2959-0

Breast cancer incidence in postmenopausal women with osteoporosis or low bone mass using arzoxifene.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-2959-0

Selective estrogen receptor modulators in clinical practice: a safety overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-2959-0

The selective estrogen receptor modulator bazedoxifene inhibits hormone-independent breast cancer cell growth and down-regulates estrogen receptor α and cyclin D1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-2959-0

Sustained efficacy and safety of bazedoxifene in preventing fractures in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-2959-0

Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-2959-0

Breast cancer risk reduction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-2959-0

Use of tamoxifen and raloxifene for breast cancer chemoprevention in 2010

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-2959-0

BRCA1/BRCA2 mutation status and analysis of cancer family history in participants of the Royal Marsden Hospital tamoxifen chemoprevention trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-2959-0

Outcomes of Tamoxifen Chemoprevention for Breast Cancer in Very High-Risk Women: A Cost-Effectiveness Analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-016-2959-0

10.1007/S00280-016-2959-0

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

5 September 2017

1004847848

0 references

1 reference